Navigation Links
CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
Date:5/26/2009

animal models.

The concept behind the L.E.A.P.S. technology is to directly mimic cell/cell interactions on the dendritic and T-cell surface with synthetic peptides. The L.E.A.P.S. constructs containing the antigenic disease epitope linked to an Immune/T-cell binding ligand (I/TCBL) can be manufactured by peptide synthesis or by covalently linking the two peptides. Depending upon the type of L.E.A.P.S. construct and I/TCBL used, CEL-SCI is able to direct the outcome of the immune response towards the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). The L.E.A.P.S. vaccine constructs are chimeric peptides which combine antigen specificity with immune response modulation.

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
2. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
3. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
4. CEL-SCI Corporation Announces 2008 Financial Results
5. CEL-SCI Corporation Releases Letter to Shareholders
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Takes Delivery of New Manufacturing Facility
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
10. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
11. CEL-SCI to Present at the Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... researchers have identified a class of high-strength metal alloys ... smaller and more responsive. The alloys could be ... loudspeakers, and components that boost the performance of medical ... engines. While these nanostructured metal alloys are not ...
... Reportlinker.com announces that a new market research report ... Three Alternative Scenarios of the Future In Vitro ... http://www.reportlinker.com/p0363585/Three-Alternative-Scenarios-of-the-Future-In-Vitro-Diagnostics-Market-through-2018.html This report is ... and R&D executives. The report is designed to ...
... N.J., March 9, 2011 Palatin Technologies, Inc. (NYSE Amex: ... at the ROTH 23rd Annual OC Growth Stock Conference on ... conference will be held at the Ritz Carlton Laguna Niguel ... President and Chief Executive Officer of Palatin Technologies, will provide ...
Cached Biology Technology:Rutgers researchers identify materials that may deliver more 'bounce' 2Reportlinker Adds Three Alternative Scenarios of the Future In Vitro Diagnostics Market through 2018 2
(Date:4/16/2014)... ,, Imagine you cannot move your eyes up, and you cannot ... tilted upward so that your eyes look straight when they are ... be corrected to allow people a normal position of their head. ... why this happens. , In a paper published in the April ...
(Date:4/16/2014)... bulbar muscular atrophy (SBMA) is a rare inherited neuromuscular disorder ... long considered it to be essentially an affliction of primary ... brainstem that control muscle movement. , But in a new ... Neuron , a team of scientists at the University ...
(Date:4/16/2014)... array of finger-like projections called microvilli covers the ... University researchers have now discovered how intestinal cells build ... and defending against pathogens. The findings, published April 10 ... for adhesion molecules in brush border assembly and increase ...
Breaking Biology News(10 mins):Researchers track down cause of eye mobility disorder 2Mutant protein in muscle linked to neuromuscular disorder 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 3
... A study led by St. Jude Children,s Research Hospital has ... of nerve cells in amyotrophic lateral sclerosis (ALS), also known ... same mutation occurred in both genes and led to the ... an essential role in normal RNA functioning and have also ...
... An international group of researchers has discovered seven ... with increased risk of age-related macular degeneration (AMD), a ... network of international investigators representing 18 research groups, also ... which is published online in Nature Genetics ...
... CHAMPAIGN, Ill. A study published in the journal ... late 1800s in West Central Illinois. The study could not ... says a co-author of the new research., Charles Robertson, a ... and the University of Illinois, was one of the first ...
Cached Biology News:2 new genes linked to amyotrophic lateral sclerosis and related disorders 22 new genes linked to amyotrophic lateral sclerosis and related disorders 3International consortium discovers seven new genomic regions associated with AMD 2International consortium discovers seven new genomic regions associated with AMD 3Illinois town provides a historical foundation for today's bee research 2
... Immulon 2HB ELISA strips, high binding ... affinity for hydrophilic proteins and complexes. ... for reagent injection while providing the ... Each strip accomodates 12 wells., ...
...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
Biology Products: